Levofloxacin Anhydrous

Summary

Levofloxacin Anhydrous (CHEMBL33) is an approved small-molecule DNA synthesis inhibitor; indicated across 4 conditions including overactive bladder and tuberculosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 204
• Chemistry: C18H20FN3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL33
Name	Levofloxacin Anhydrous
Type	Small molecule
Max phase	4
ChEBI	CHEBI:63598
Molecular formula	C18H20FN3O4
InChIKey	GSDSWSVVBLHKDQ-JTQLQIEISA-N

SMILES: C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23

ChEBI definition: An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.

Pharmacological roles (ChEBI): DNA synthesis inhibitor, antibacterial drug, topoisomerase IV inhibitor, EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor.

Also known as: Levofloxacin (anhydrous), Levofloxacin anhydrous, Levofloxacine (anhydrous), Levofloxacino (anhydrous), NSC-758709, Ofloxacin s-(-)-form, LEVOFLOXACIN ANHYDROUS, Levofloxacin, levofloxacin, Levoflaxacin, Levoflaxin

Parent form; salt/anhydrous children: CHEMBL2237108, CHEMBL5315124

Patent coverage: 14,240 distinct patent families (43,403 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tubulin.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
overactive bladder	1	MONDO:0006624	EFO:1000781
tuberculosis	1	MONDO:0018076	MONDO:0018076
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 204.

Phase distribution

Phase	Trials
PHASE4	63
PHASE3	62
Not specified	30
PHASE2	21
PHASE2/PHASE3	11
PHASE1	10
PHASE1/PHASE2	6
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05061732	PHASE4	RECRUITING	Helicobacter Pylori Eradication and Follow-up
NCT05398679	PHASE4	RECRUITING	Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
NCT06172010	PHASE4	RECRUITING	Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
NCT06200779	PHASE4	NOT_YET_RECRUITING	Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
NCT06494072	PHASE4	RECRUITING	Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
NCT06741917	PHASE4	ENROLLING_BY_INVITATION	Retrograde Intrarenal Surgery Low Risk Trial
NCT07021729	PHASE4	NOT_YET_RECRUITING	Comparison of Two Treatment Regimens of Helicobacter Pylori Infection
NCT07040839	PHASE4	NOT_YET_RECRUITING	Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
NCT07320534	PHASE4	NOT_YET_RECRUITING	Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
NCT00035347	PHASE4	COMPLETED	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
NCT00239161	PHASE4	TERMINATED	Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin
NCT00245791	PHASE4	TERMINATED	Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time
NCT00392275	PHASE4	COMPLETED	Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00429975	PHASE4	TERMINATED	Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
NCT00495339	PHASE4	COMPLETED	MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
NCT00645073	PHASE4	COMPLETED	Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis
NCT00665327	PHASE4	COMPLETED	Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
NCT00752947	PHASE4	UNKNOWN	Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
NCT00840580	PHASE4	COMPLETED	Effect on Wound Healing of Vigamox Versus Cravit
NCT01034176	PHASE4	COMPLETED	BK Treatment Study
NCT01353339	PHASE4	COMPLETED	Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study
NCT01467297	PHASE4	COMPLETED	Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB)
NCT01524302	PHASE4	COMPLETED	Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
NCT01742429	PHASE4	COMPLETED	Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
NCT02018081	PHASE4	COMPLETED	Pharmacokinetics of Levofloxacin in Intensive Care Unit
NCT02028754	PHASE4	COMPLETED	A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms
NCT02094703	PHASE4	UNKNOWN	The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
NCT02466919	PHASE4	COMPLETED	Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients
NCT02600806	PHASE4	UNKNOWN	Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients
NCT02618057	PHASE4	UNKNOWN	Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia
NCT02693574	PHASE4	UNKNOWN	Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori
NCT02757365	PHASE4	UNKNOWN	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02901288	PHASE4	UNKNOWN	Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
NCT02935010	PHASE4	COMPLETED	Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment
NCT02988089	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
NCT03087656	PHASE4	UNKNOWN	Antibiotics to Decrease Post ERCP Cholangitis
NCT03139253	PHASE4	UNKNOWN	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03160807	PHASE4	UNKNOWN	Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections
NCT03413020	PHASE4	COMPLETED	Tailored Therapy for Helicobacter Pylori Rescue Treatment
NCT03555526	PHASE4	UNKNOWN	Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).